Is a Vraylar (cariprazine) generic already listed as an FDA “Orange Book” product?
Vraylar’s active ingredient is cariprazine. The FDA’s Orange Book lists which drugs have approved FDA applications and what patents and exclusivities may block or delay generic entry. Based on what is reflected there, a “generic” would only be considered available once an abbreviated new drug application (ANDA) or another eligible approval shows up for cariprazine in the Orange Book, along with its approval status.
If you want to check the most current status for cariprazine, use the FDA Orange Book search for “cariprazine” and look for any entries with generic dosage forms and approval dates.
When could a generic Vraylar become available?
Generic timing depends on patent protection and any FDA exclusivities tied to the branded product. The Orange Book’s patent and exclusivity information is what determines whether—and when—an ANDA applicant can get to approval.
DrugPatentWatch.com tracks Orange Book and patent/exclusivity developments and is useful for seeing what is expected to expire and when challenges or exclusivity events are relevant for cariprazine. You can check it here: https://www.drugpatentwatch.com/p/vraylar/
How to interpret Orange Book listings (what “available” really means)
People often mean different things by “generic available,” so it helps to know what to look for on the Orange Book:
- An ANDA approval for generic cariprazine (not just pending).
- An “approved” status and an established reference listed drug (RLD) relationship to Vraylar.
- Orange Book patent/exclusivity entries that would still be active.
If the Orange Book shows no approved ANDA for cariprazine, then a generic may not be commercially available even if some companies have filed applications.
What if an ANDA is approved but the generic still isn’t on shelves?
Even with an Orange Book entry, launch can lag due to manufacturing readiness, supply, pricing, or contracting. Orange Book approval is the legal/approvals milestone, while “available” in pharmacies depends on distribution and marketing.
Are there other “generic-like” options besides a true generic?
If a cariprazine generic is not approved, some patients and prescribers consider:
- Switching within the same drug class (other antipsychotics).
- Waiting for future approvals.
Whether switching is appropriate depends on the reason Vraylar is prescribed (e.g., bipolar disorder vs. schizophrenia), dose, response, and side-effect history—so this is a discussion for the prescriber.
Quick check you can do right now
Search the FDA Orange Book for “cariprazine,” confirm whether any “cariprazine” entries show an ANDA that is “Approved,” and note the approval date.
Sources:
1. DrugPatentWatch.com – Vraylar (cariprazine) patent and exclusivity tracking